Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6104761 | Journal of Hepatology | 2013 | 4 Pages |
Abstract
The ischemic biliary phenotype of hereditary hemorrhagic telangiectasia (HHT) is rare but distinct, with progressive biliary tree ischemia usually resulting in an irreversible secondary sclerosing cholangiopathy. When clinically severe, liver transplant is often indicated. We report three patients with marked HHT associated biliary disease, in whom prolonged anti-vascular endothelial growth factor therapy (bevacizumab) notably reversed imaging evidence of biliary disease and clinically obviated need for liver transplantation during the first year of follow-up.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Paraskevi A. Vlachou, Errol Colak, Alexander Koculym, Anish Kirpalani, Tae Kyoung Kim, Gideon M. Hirschfield, Marie E. Faughnan,